Back to News
Market Impact: 0.2
Lunit And Summit Collaborate On AI-Powered Biomarker Discovery For Ivonescimab
Source: Nasdaq
Artificial IntelligenceHealthcare & BiotechTechnology & Innovation
Lunit and Summit Therapeutics announced a research agreement to evaluate Lunit SCOPE IO, Lunit’s AI-powered pathology platform, for tumour microenvironment analysis. The work will support Summit’s immuno-oncology development programs for ivonescimab; the article provides no financial terms or research results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
SMMT0.45
More News
- From Wall Street to Silicon Valley, Anthropic IPO poised to have massive 'trickle-down effect'
- A shock in Brazil sends stocks plunging, while neoclouds take another hit
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs
- EQT becomes the nation’s leading natural gas ‘juggernaut’ with a $13B deal as data center, export demand surges
- Microsoft offers buyouts to nearly 30% of workforce in ongoing AI shift
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis